FMI - Foundation Medicine, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
136.85
0.00 (0.00%)
As of 2:50PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close136.85
Open136.85
Bid136.80 x 29200
Ask136.85 x 4000
Day's Range136.80 - 136.90
52 Week Range31.70 - 137.20
Volume230,162
Avg. Volume572,407
Market Cap5.082B
Beta1.54
PE Ratio (TTM)N/A
EPS (TTM)-4.21
Earnings DateJul 30, 2018 - Aug 3, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est95.00
Trade prices are not sourced from all markets
  • Mattel, Foundation Medicine and Sirius are the Yahoo Finance Charts of the day.
    Yahoo Finance Video29 days ago

    Mattel, Foundation Medicine and Sirius are the Yahoo Finance Charts of the day.

    Let's check out the Yahoo Finance charts of the day. Mattel (MAT): Shares are down in early trade, at around 2.9%.  The toy maker was downgraded to "neutral" from "buy" at UBS, which still sees value in the brand but notes the stock's 35 percent jump from its March lows despite little change in fundamentals. Foundation Medicine (FMI): Shares up here, around 28.5%.  Roche Holding said it would pay $2.4 billion to buy the shares it doesn't already own in Foundation Medicine. The Swiss drug giant presently owns 57% of Foundation and will pay $137 a share for the U.S based company. Sirius (SIRI): Shares down here, at around 1.7%. The satellite radio operator was downgraded to "hold" from "buy" at Pivotal Research in a valuation call. Pivotal's target price for the Sirius stock remains at $7.75 per share. For more on today's big stock movers check out the Final Round, live at 3:55 p.m. ET, right here on Yahoo Finance.

  • Netflix expands and has price target raised, Amazon teams up with Marriott hotels, Wells Fargo merging wealth management groups
    Yahoo Finance Video29 days ago

    Netflix expands and has price target raised, Amazon teams up with Marriott hotels, Wells Fargo merging wealth management groups

    Netflix, Amazon, Wells Fargo, Roche and Apple are the companies to watch.

  • 3 Best Biotech Acquisitions of 2018 (So Far)
    Motley Fool13 days ago

    3 Best Biotech Acquisitions of 2018 (So Far)

    There were bigger biotech deals than these this year, but arguably none better.

  • GlobeNewswire16 days ago

    Roche commences tender offer for all shares of Foundation Medicine, Inc. for US$ 137.00 per share in cash

    OTCQX: RHHBY) today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Foundation Medicine, Inc. (NASDAQ: FMI) at a price of US$ 137.00 per share. The tender offer is being made pursuant to the previously announced merger agreement dated as of 18 June 2018 among Foundation Medicine, Inc., Roche Holdings, Inc., an indirect wholly owned subsidiary of Roche Holding Ltd, and 062018 Merger Subsidiary, Inc., a wholly owned subsidiary of Roche Holdings, Inc. The tender offer period will expire at 12am midnight, Eastern Time, at the end of the day on 30 July 2018, unless the offer is extended.

  • Motley Fool23 days ago

    What Roche's Acquisition of Foundation Medicine Means for Investors

    Roche makes a big bet on precision oncology.

  • Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI
    Zacks26 days ago

    Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI

    Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.

  • Motley Fool26 days ago

    Big Biotech Stock Pops and Drops This Week

    Foundation Medicine, Sarepta Therapeutics, and PTC Therapeutics reported market-moving news that every biotech investor ought to know about.

  • The Wall Street Journal26 days ago

    [$$] Gormley's Take: Precision-Medicine Drive Gathers Momentum

    Last month, the American Cancer Society expanded opportunities for colorectal cancer-testing companies when it called for people with average risk profiles to begin screening at age 45 instead of 50. Inc., which went public in 2005, said clinical trials showed its Oncotype DX test could definitively identify which early-stage breast cancer patients would and wouldn’t benefit from chemotherapy—news that propelled its stock price to all-time highs. Inc., which Third Rock Ventures formed in 2009 and took public in 2013.

  • Company News For Jun 20, 2018
    Zacks28 days ago

    Company News For Jun 20, 2018

    Companies in the news are: T,FMI,COTV,SRPT

  • ACCESSWIRE28 days ago

    Today’s Research Reports on Stocks to Watch: Foundation Medicine and Solid Biosciences

    NEW YORK, NY / ACCESSWIRE / June 20, 2018 / Shares of Foundation Medicine exploded on Tuesday after announcing that it has entered into a definitive merger agreement for Roche to acquire the outstanding shares of FMI`s common stock not already owned by Roche and its affiliates at a price of US$ 137.00 per share. Shares of Solid Biosciences also broke out after announcing that the FDA has lifted a clinical hold on the company's phase I/II trial, IGNITE DMD, for its experimental candidate, SGT-001. Foundation Medicine, Inc. shares closed up 28.46% on Tuesday, with about 6.3 million shares traded compared to an average trading volume of about 409,00 shares.

  • Roche to Buy Rest of Foundation Medicine for $2.4 billion
    Zacks28 days ago

    Roche to Buy Rest of Foundation Medicine for $2.4 billion

    Roche inks a deal with Foundation Medicine to acquire the remaining shares of Foundation Medicine, not already owned by it for a total consideration of $2.4 billion.

  • The Wall Street Journal29 days ago

    [$$] Roche to Pay $2.4 Billion for Full Control of Foundation Medicine

    Roche Holding AG on Tuesday said it would pay $2.4 billion to buy the shares it doesn’t already own in Foundation Medicine Inc., furthering its bet on personalized cancer care. The Swiss drug giant, which already owns roughly 57% of Foundation, will pay $137 a share for the U.S.-based company, valuing it at $5.3 billion. Cambridge, Mass.-based Foundation makes molecular-diagnostic tests that identify alterations in a patient’s cancer.

  • PR Newswire29 days ago

    WeissLaw LLP: Foundation Medicine, Inc. Acquisition May Not Be In The Best Interest of FMI Shareholders

    NEW YORK , June 19, 2018 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Foundation Medicine, Inc. ("FMI" ...

  • Why CVS Health, Foundation Medicine, and Solid Biosciences Jumped Today
    Motley Fool29 days ago

    Why CVS Health, Foundation Medicine, and Solid Biosciences Jumped Today

    Find out why healthcare made a big leap in today's market action.

  • How A Merger Will Help These Two Firms Tailor Cancer Treatments
    Investor's Business Daily29 days ago

    How A Merger Will Help These Two Firms Tailor Cancer Treatments

    Foundation Medicine rocketed to a record high Tuesday after Swiss drugmaker Roche agreed to buy it in a pharmaceutical merger for $2.4 billion.

  • Roche Does Pharma M&A Without the Pharma
    Bloomberg29 days ago

    Roche Does Pharma M&A Without the Pharma

    The Swiss giant agreed Tuesday to pay $2.4 billion to buy out the remaining shareholders in Foundation Medicine Inc., a cancer-focused gene sequencing company in which it holds a more than 50 percent stake. It follows Roche's $1.9 billion purchase earlier this year of Flatiron Health Inc., which collects and analyzes real-world data on how cancer patients are treated. These were Roche’s two biggest deals since 2014. The Foundation deal comes at a hefty premium, and may be a disappointment to investors who would have preferred a more typical acquisition focused on an actual, existing drug.

  • Why Foundation Medicine Stock Is Skyrocketing 28.3% Higher Today
    Motley Fool29 days ago

    Why Foundation Medicine Stock Is Skyrocketing 28.3% Higher Today

    The company's being acquired by long-time partner Roche Holdings.

  • Netflix expands, Amazon teams up with Marriott, Wells Fargo merging wealth management groups
    Yahoo Finance29 days ago

    Netflix expands, Amazon teams up with Marriott, Wells Fargo merging wealth management groups

    Netflix, Amazon, Wells Fargo, Roche and Apple are the companies to watch.

  • Stocks fall deep into the red as trade war escalates
    Yahoo Finance29 days ago

    Stocks fall deep into the red as trade war escalates

    Yahoo Finance's LIVE market coverage and analysis of what you need to watch in the stock market begins each day at 9:25 a.m. ET.

  • The Wall Street Journal29 days ago

    [$$] European Corporate Roundup for Tuesday

    A $2.4 billion Roche acquisition and another Debenhams profit warning are the European corporate highlights Tuesday.

  • Roche pays $2.4 billion for rest of cancer expert Foundation Medicine
    Reuters29 days ago

    Roche pays $2.4 billion for rest of cancer expert Foundation Medicine

    ZURICH/LONDON (Reuters) - Swiss drugmaker Roche is paying $2.4 billion to buy the rest of Foundation Medicine (FMI), raising its bet on the U.S. genomic profiling group's ability to personalise cancer care. The deal, backed by the boards of both companies, is worth $137 per share - a premium of 29 percent to FMI's closing price on Monday - valuing the Cambridge, Massachusetts-based company at $5.3 billion. It is the latest in a series of bolt-on acquisitions by Roche as the world's largest marker of cancer drugs seeks to tap into promising technology developed by biotech companies to drive future growth as its older drugs face competition.

  • The Wall Street Journal29 days ago

    [$$] Roche to Buy Rest of Foundation Medicine

    The Swiss drug giant, which already owns roughly 57% of Foundation, will pay $137 a share for the U.S.-based company, valuing it at $5.3 billion. Cambridge, Mass.-based Foundation makes molecular-diagnostic tests that identify alterations in a patient’s cancer. The deal to take full control of Foundation comes after Roche first bought a stake in the company in 2015.

  • Roche pays $2.4 billion for rest of cancer expert Foundation Medicine
    Reuters29 days ago

    Roche pays $2.4 billion for rest of cancer expert Foundation Medicine

    ZURICH/LONDON (Reuters) - Swiss drugmaker Roche (ROG.S) is paying $2.4 billion to buy the rest of Foundation Medicine (FMI) (FMI.O), raising its bet on the U.S. genomic profiling group's ability to personalize cancer care. The deal, backed by the boards of both companies, is worth $137 per share - a premium of 29 percent to FMI's closing price on Monday - valuing the Cambridge, Massachusetts-based company at $5.3 billion. It is the latest in a series of bolt-on acquisitions by Roche as the world's largest marker of cancer drugs seeks to tap into promising technology developed by biotech companies to drive future growth as its older drugs face competition.